News & Events

View

Lucence Announces Publication of Validation Study for LiquidHALLMARK ctDNA Liquid Biopsy Assay

Lucence’s LiquidHALLMARK Liquid Biopsy Assay Expands to Include cfRNA

10 January 2022

Liquid Biopsy Screening Study

Lucence Launches First Liquid Biopsy Screening Study in Partnership with the VA Palo Alto Healthcare System

11 November 2021

AstraZeneca and Lucence Collaborate in South-East Asia to bring HRD Testing to Ovarian Cancer Patients to guide PARPi Treatment

10 November 2021

Lucence and Yemaachi Launch the AMBER Study to Detect and Characterize Genomic Alterations in Breast Cancer in Women in Africa and Expand Liquid Biopsy Access

26 October 2021

Lucence Presents Data at ESMO 2021 Showing Liquid Biopsy Detects Actionable Genomic Alterations in Bladder Cancer Patients Undergoing Immunotherapy

15 September 2021

Lucence Announces Commercial Availability of Tissue500™ for Comprehensive Targeted Therapy Matching

14 September 2021

Lucence Presents Real-World Evidence on Applications of Liquid Biopsy at 2021 ASCO, Announces Formation of Medical Advisory Board

1
2

Lucence announces publication of validation study for LiquidHALLMARK®, establishing the assay’s sensitivity.

>